Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng Purchases 10,000 Shares of Stock

Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng acquired 10,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were bought at an average cost of $2.58 per share, for a total transaction of $25,800.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $25,800. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immix Biopharma Trading Up 5.1 %

Shares of IMMX stock opened at $2.67 on Friday. The firm has a fifty day moving average price of $2.14 and a 200 day moving average price of $2.10. The company has a market cap of $43.49 million, a P/E ratio of -3.34 and a beta of 0.14. Immix Biopharma, Inc. has a 12 month low of $0.68 and a 12 month high of $3.29.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Friday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). On average, equities analysts forecast that Immix Biopharma, Inc. will post -0.87 EPS for the current year.

Hedge Funds Weigh In On Immix Biopharma

Several large investors have recently bought and sold shares of IMMX. XTX Topco Ltd acquired a new position in Immix Biopharma in the first quarter valued at $31,000. Renaissance Technologies LLC acquired a new position in Immix Biopharma in the first quarter valued at $151,000. Virtu Financial LLC acquired a new position in Immix Biopharma in the first quarter valued at $57,000. State Street Corp acquired a new position in Immix Biopharma in the second quarter valued at $100,000. Finally, Vanguard Group Inc. boosted its stake in Immix Biopharma by 106.5% in the third quarter. Vanguard Group Inc. now owns 105,125 shares of the company’s stock valued at $143,000 after acquiring an additional 54,220 shares in the last quarter. Institutional investors and hedge funds own 3.97% of the company’s stock.

Analyst Ratings Changes

Separately, Roth Mkm reiterated a “buy” rating and set a $14.00 target price on shares of Immix Biopharma in a research note on Monday, August 14th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.